-
MRKR Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Marker Therapeutics (MRKR)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.00 mm | 9.00 mm | 9.00 mm | 9.00 mm | 9.00 mm | 9.00 mm |
Cash burn (monthly) | (no burn) | 760.20 k | 799.96 k | 871.42 k | (no burn) | 611.22 k |
Cash used (since last report) | n/a | 3.85 mm | 4.05 mm | 4.41 mm | n/a | 3.10 mm |
Cash remaining | n/a | 5.15 mm | 4.95 mm | 4.59 mm | n/a | 5.90 mm |
Runway (months of cash) | n/a | 6.8 | 6.2 | 5.3 | n/a | 9.7 |
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 8 |
Closed positions | 3 |
Increased positions | 8 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 49.24 bn |
Total shares | 10.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Eastern Capital | 3.97 mm | $0.00 |
NEA Management | 1.63 mm | $5.06 bn |
New Enterprise Associates 16 | 1.63 mm | $4.00 mm |
Alyeska Investment | 915.59 k | $38.49 bn |
Blue Owl Capital | 554.25 k | $1.72 bn |
Aisling Capital IV | 464.29 k | $8.64 mm |
Hudson Bay Capital Management | 331.67 k | $958.43 mm |
Aisling Capital Management | 325.37 k | $1.01 bn |
Vanguard | 243.12 k | $756.11 mm |
LPL Financial | 79.73 k | $247.96 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Feb 25 | Vera Juan | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.59 | 50,000 | 79.50 k | 50,000 |
12 Feb 25 | Norman David Eansor | Stock Option Common Stock | Grant | Acquire A | No | No | 1.59 | 30,000 | 47.70 k | 30,000 |
12 Feb 25 | Katharine Knobil | Stock Option Common Stock | Grant | Acquire A | No | No | 1.59 | 30,000 | 47.70 k | 30,000 |
12 Feb 25 | Steve Elms | Stock Option Common Stock | Grant | Acquire A | No | No | 1.59 | 30,000 | 47.70 k | 30,000 |
23 Dec 24 | New Enterprise Associates 16 | Common Stock | Buy | Acquire P | No | No | 3.2 | 554,250 | 1.77 mm | 1,625,678 |